2026 DTC and DTP Pharma Benchmark Survey

This report reveals that compliance challenges are fragmenting organizations' visibility into the patient journey. The current privacy landscape is creating blind spots that not only waste resources but also limit growth opportunities. This report is based on two comprehensive surveys of 100 marketing leaders and 100 privacy leaders across top-25 global pharma companies, mid-sized or specialty pharma organizations, and biotech or emerging biopharma firms. The research uncovers how rising regulatory enforcement from the FTC and state privacy laws is reshaping DTC/DTP strategy.